Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 1000 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The firm has a fifty day moving average of C$0.01 and a two-hundred day moving average of C$0.01. The company has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- What is the Nikkei 225 index?
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- Manufacturing Stocks Investing
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
